Clinical trial
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell…
NCT00453427 · Ontario Clinical Oncology Group (OCOG), Other · Completed
Key facts
| NCT number | NCT00453427 |
|---|---|
| Title | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas |
| Official title | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas: A Multi-centre Phase I and II Study |
| Acronym | ACCAPELA |
| Lead sponsor | Ontario Clinical Oncology Group (OCOG), Other |
| Collaborators | Sunnybrook Health Sciences Centre Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-cell Lymphomas |
| Intervention type | Drug |
| Interventions | Alemtuzumab (Campath-1H) |
| Enrollment | 20 |
| Start date | Sep 1, 2006 |
| Primary completion | Jun 1, 2013 |
| Completion | May 1, 2015 |
| First posted | Mar 29, 2007 |
| Last update posted | Jun 3, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: